Aigen Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Aigen Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14,598	Closed	-$868K	–	538
2025 Q4	$868K	Buy	+14,598	New	+$795K	0.2%	141
2025 Q3	–	Sell	-62,549	Closed	-$3.44M	–	804
2025 Q2	$3.44M	Buy	+62,549	New	+$3.68M	0.47%	30
2023 Q4	–	Sell	-8,691	Closed	-$769K	–	807
2023 Q3	$769K	Buy	8,691 +1,521	+21%	+$135K	0.14%	228
2023 Q2	$621K	Buy	+7,170	New	+$675K	0.09%	295
2022 Q2	–	Sell	-4,763	Closed	-$367K	–	538
2022 Q1	$367K	Sell	4,763 -497	-9%	-$41.6K	0.06%	330
2021 Q4	$446K	Buy	+5,260	New	+$434K	0.03%	670
2021 Q2	–	Sell	-7,317	Closed	-$553K	–	482
2021 Q1	$553K	Buy	+7,317	New	+$598K	0.07%	275
2020 Q2	–	Sell	-1,071	Closed	-$91K	–	847
2020 Q1	$91K	Buy	+1,071	New	+$92.3K	0.01%	879

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aigen Investment Management's BMRN Position: Q1 2026 in Review

Aigen Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 14,598 shares — an estimated $868K sold.

Aigen Investment Management first reported a position in BMRN in Q1 2020 and held it in 8 quarters. The position peaked at $3.44M in Q2 2025. 559 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Aigen Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Aigen Investment Management sold 14,598 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $868K.
Aigen Investment Management first reported a position in BioMarin Pharmaceuticals in Q1 2020 and held it in 8 quarters.
Aigen Investment Management's BioMarin Pharmaceuticals position peaked at $3.44M in Q2 2025.
559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Aigen Investment Management's 13F filing for Q1 2026, filed 15 May 2026.